Hazem Elkady

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 34

Top Topics

Molecular Docking

Tyrosine Kinase

Top Venues

Molecules (Basel, Switzerland)

Journal of biomolecular structure & dynamics

This page only lists publications with an associated author ORCID identifier.

Publications

Anas Ramadan Kotb, Abdallah E Abdallah, Hazem Elkady, Ibrahim H Eissa, Mohammed S Taghour, Dina Abed Bakhotmah, Tamer M Abdelghany, Mohamed Ayman El-Zahabi
Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents. RSC advances 13 (16) (2023)
Hazem Elkady, Osama A El-Dardir, Elwan Alaa, Mohammed S Taghour, Hazem A Mahdy, Mohammed A Dahab, Eslam B Elkaeed, Bshra A Alsfouk, Ibrahim M Ibrahim, Dalal Z Husein, Elsayed E Hafez, Amira Muhammad Galal Darwish, Ahmed M Metwaly, Ibrahim H Eissa
Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors. RSC advances 13 (40) (2023)
Souad A El-Metwally, Hazem Elkady, Muhammad A Hagras, Eslam B Elkaeed, Bshra Ali A Alsfouk, Ahmed S Doghish, Ibrahim M Ibrahim, Mohammed S Taghour, Dalal Z Husein, Ahmed M Metwaly, Ibrahim H Eissa
Discovery of new VEGFR-2 inhibitors and apoptosis inducer-based thieno[2,3- d ]pyrimidine. Future medicinal chemistry (2023)
Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Mohamed S Alesawy, Hazem Elkady, Ahmed M Metwaly
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach. PloS one 18 (3) (2023)
Ibrahim H Eissa, Reda G Yousef, Hazem Elkady, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Mostafa A Elhendawy, Murrell Godfrey, Ahmed M Metwaly
Identification of new theobromine-based derivatives as potent VEGFR-2 inhibitors: design, semi-synthesis, biological evaluation, and in silico studies. RSC advances 13 (33) (2023)
Mohammed S Taghour, Hazem Elkady, Wagdy M Eldehna, Nehal El-Deeb, Ahmed M Kenawy, Abeer E Abd El-Wahab, Eslam B Elkaeed, Bshra A Alsfouk, Ahmed M Metwaly, Ibrahim H Eissa
Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies. Journal of biomolecular structure & dynamics (2023)
Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Mohamed S Alesawy, Hazem Elkady, Ahmed M Metwaly
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach. PloS one 18 (3) (2023)
Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Mohamed S Alesawy, Hazem Elkady, Ahmed M Metwaly
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach. PloS one 18 (3) (2023)
Hazem Elkady, Khaled El-Adl, Helmy Sakr, Adel S Abdelraheem, Sally I Eissa, Mohamed Ayman El-Zahabi
Novel promising benzoxazole/benzothiazole-derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis. Archiv der Pharmazie (2023)
Ibrahim H Eissa, Reda G Yousef, Hazem Elkady, Aisha A Alsfouk, Bshra Ali A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Eslam B Elkaeed, Ahmed M Metwaly
A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study. Life (Basel, Switzerland) 13 (1) (2023)
Walid E Elgammal, Hazem Elkady, Hazem A Mahdy, Dalal Z Husein, Aisha A Alsfouk, Bshra A Alsfouk, Ibrahim M Ibrahim, Eslam B Elkaeed, Ahmed M Metwaly, Ibrahim H Eissa
Rationale design and synthesis of new apoptotic thiadiazole derivatives targeting VEGFR-2: computational and in vitro studies. RSC advances 13 (51) (2023)
Hazem A Mahdy, Hazem Elkady, Mohammed S Taghour, Elwan Alaa, Mohammed A Dahab, Mohamed A Elkady, Elsayed Ge Elsakka, Eslam B Elkaeed, Bshra Ali A Alsfouk, Ibrahim M Ibrahim, Ibrahim H Eissa, Ahmed M Metwaly
New theobromine derivatives inhibiting VEGFR-2: design, synthesis, antiproliferative, docking and molecular dynamics simulations. Future medicinal chemistry (2023)
Ibrahim H Eissa, Reda G Yousef, Hazem Elkady, Aisha A Alsfouk, Bshra Ali A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Eslam B Elkaeed, Ahmed M Metwaly
A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study. Life (Basel, Switzerland) 13 (1) (2023)
Mohammed A Dahab, Hazem A Mahdy, Hazem Elkady, Mohammed S Taghour, Alaa Elwan, Mohamed A Elkady, Elsayed G E Elsakka, Eslam B Elkaeed, Aisha A Alsfouk, Ibrahim M Ibrahim, Ahmed M Metwaly, Ibrahim H Eissa
Semi-synthesized anticancer theobromine derivatives targeting VEGFR-2: in silico and in vitro evaluations. Journal of biomolecular structure & dynamics (2023)
Walid E Elgammal, Hazem Elkady, Hazem A Mahdy, Dalal Z Husein, Aisha A Alsfouk, Bshra A Alsfouk, Ibrahim M Ibrahim, Eslam B Elkaeed, Ahmed M Metwaly, Ibrahim H Eissa
Rationale design and synthesis of new apoptotic thiadiazole derivatives targeting VEGFR-2: computational and in vitro studies. RSC advances 13 (51) (2023)
Eslam B Elkaeed, Bshra A Alsfouk, Tuqa H Ibrahim, Reem K Arafa, Hazem Elkady, Ibrahim M Ibrahim, Ibrahim H Eissa, Ahmed M Metwaly
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach. Antiviral therapy 28 (5) (2023)
Ibrahim H Eissa, Reda G Yousef, Eslam B Elkaeed, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Mohamed S Alesawy, Hazem Elkady, Ahmed M Metwaly
Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach. PloS one 18 (3) (2023)
Mohamed Ayman El-Zahabi, Hazem Elkady, Helmy Sakr, Adel S Abdelraheem, Sally I Eissa, Khaled El-Adl
Design, synthesis, anticancer evaluation, in silico docking and ADMET analysis of novel indole-based thalidomide analogs as promising immunomodulatory agents. Journal of biomolecular structure & dynamics (2023)
Ibrahim H Eissa, Reda G Yousef, Hazem Elkady, Aisha A Alsfouk, Bshra Ali A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Eslam B Elkaeed, Ahmed M Metwaly
A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study. Life (Basel, Switzerland) 13 (1) (2023)
Souad A El-Metwally, Hazem Elkady, Mohamed Hagras, Dalal Z Husein, Ibrahim M Ibrahim, Mohammed S Taghour, Hesham A El-Mahdy, Ahmed Ismail, Bshra A Alsfouk, Eslam B Elkaeed, Ahmed M Metwaly, Ibrahim H Eissa
Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies of new thieno[2,3- d ]pyrimidines targeting VEGFR-2. RSC advances 13 (33) (2023)
Reda G Yousef, Ibrahim H Eissa, Hazem Elkady, Wagdy M Eldehna, Ahmed B M Mehany, Ahmed Nabeeh, Ibrahim M Ibrahim, Alaa Elwan, Mohamed Ayman El-Zahabi
New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis, in vitro , and in silico studies. Journal of biomolecular structure & dynamics (2023)
Ibrahim H Eissa, Reda G Yousef, Hazem Elkady, Aisha A Alsfouk, Bshra Ali A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Eslam B Elkaeed, Ahmed M Metwaly
A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study. Life (Basel, Switzerland) 13 (1) (2023)
Eslam B Elkaeed, Reda G Yousef, Hazem Elkady, Ibraheem M M Gobaara, Bshra Ali A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Ahmed M Metwaly, Ibrahim H Eissa
Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects. Molecules (Basel, Switzerland) 27 (14) (2022)
Amany Belal, Mohamed A Elanany, Eman Y Santali, Ahmed Ali Al-Karmalawy, Moustafa O Aboelez, Ali H Amin, Magda H Abdellatif, Ahmed B M Mehany, Hazem Elkady
Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management. Molecules (Basel, Switzerland) 27 (11) (2022)
Anas Ramadan Kotb, Dina A Bakhotmah, Abdallah E Abdallah, Hazem Elkady, Mohammed S Taghour, Ibrahim H Eissa, Mohamed Ayman El-Zahabi
Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents. RSC advances 12 (52) (2022)
Reda G Yousef, Hazem Elkady, Eslam B Elkaeed, Ibraheem M M Gobaara, Hanan A Al-Ghulikah, Dalal Z Husein, Ibrahim M Ibrahim, Ahmed M Metwaly, Ibrahim H Eissa
( E )- N -(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth Factor Receptor-2: Synthesis, Computational, and Anticancer Studies. Molecules (Basel, Switzerland) 27 (22) (2022)
Eslam B Elkaeed, Ibrahim H Eissa, Hazem Elkady, Ahmed Abdelalim, Ahmad M Alqaisi, Aisha A Alsfouk, Elwan Alaa, Ahmed M Metwaly
A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease. International journal of molecular sciences 23 (15) (2022)
Elwan Alaa, Abdallah E Abdallah, Hazem A Mahdy, Mohammed A Dahab, Mohammed S Taghour, Eslam B Elkaeed, Ahmed B M Mehany, Ahmed Nabeeh, Mohammed Adel, Aisha A Alsfouk, Hazem Elkady, Ibrahim H Eissa
Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules (Basel, Switzerland) 27 (15) (2022)
Eslam B Elkaeed, Fadia S Youssef, Ibrahim H Eissa, Hazem Elkady, Aisha A Alsfouk, Mohamed L L Ashour, Mahmoud A El Hassab, Sahar M Abou-Seri, Ahmed M Metwaly
Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. International journal of molecular sciences 23 (13) (2022)
Anas Ramadan Kotb, Dina A Bakhotmah, Abdallah E Abdallah, Hazem Elkady, Mohammed S Taghour, Ibrahim H Eissa, Mohamed Ayman El-Zahabi
Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents. RSC advances 12 (52) (2022)
Eslam B Elkaeed, Reda G Yousef, Hazem Elkady, Aisha A Alsfouk, Dalal Z Husein, Ibrahim M Ibrahim, Ahmed M Metwaly, Ibrahim H Eissa
New Anticancer Theobromine Derivative Targeting EGFR WT and EGFR T790M : Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies. Molecules (Basel, Switzerland) 27 (18) (2022)
Amany Belal, Hazem Elkady, Ahmed Ali Al-Karmalawy, Ali H Amin, Mohammed M Ghoneim, Mohamed El Sherbiny, Rasha Hamed Al-Serwi, Mohamed Attia Abdou, Mona H Ibrahim, Ahmed B M Mehany
Discovery of Some Heterocyclic Molecules as Bone Morphogenetic Protein 2 (BMP-2)-Inducible Kinase Inhibitors: Virtual Screening, ADME Properties, and Molecular Docking Simulations. Molecules (Basel, Switzerland) 27 (17) (2022)
Nawaf A Alsaif, Mohammed S Taghour, A F M Motiur Rahman, Ahmad J Obaidullah, Abdulrahman A Al-Mehizia, Manal M Alanazi, Saleh Aldawas, Elwan Alaa, Hazem Elkady
Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. Journal of enzyme inhibition and medicinal chemistry 36 (1) (2021)
Mohammed M Alanazi, Hazem Elkady, Nawaf A Alsaif, Ahmad J Obaidullah, Hamad M Al Kahtani, Manal M Alanazi, Madhawi A Alharbi, Ibrahim H Eissa, Mohammed A Dahab
New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC advances 11 (48) (2021)